Strahlentherapie und Onkologie

, Volume 188, Issue 10, pp 926–932 | Cite as

Testicular radiation dose after multimodal curative therapy for locally advanced rectal cancer

Influence on hormone levels, quality of life, and sexual functioning
  • S. Hennies
  • H.A. Wolff
  • K. Jung
  • M. Rave-Fränk
  • J. Gaedcke
  • M. Ghadimi
  • C.F. Hess
  • H. Becker
  • R.M. Hermann
  • H. Christiansen
Original article

Abstract

Purpose

The purpose of the current work was to prospectively measure the influence of testicular radiation dose on hormone levels, quality of life (QoL), and sexual functioning following multimodal therapy (neoadjuvant radiochemotherapy, surgery, and adjuvant chemotherapy) for rectal cancer.

Patients and methods

From November 2007 to November 2009, 83 male patients were treated at the University of Goettingen with radiochemotherapy (RCT) for locally advanced rectal cancer [total dose 50.4 Gy, concomitant chemotherapy with two cycles of 5-fluorouracil (FU) or 5-FU and oxaliplatin]. Testicular radiation doses were analyzed and correlated with hormone levels [luteinizing hormone (LH), follicle stimulating hormone (FSH), total testosterone and free androgen index (FAI) serum levels], QoL, and sexual functioning, which were determined before and up to 1 year after RCT.

Results

Mean dose at the testes was 3.9 Gy (range 0.28–11.98 Gy). It was higher for tumors located < 6 cm from the anocutaneous line (p < 0.05). One year after therapy, testosterone, the testosterone/LH ratio, and the FAI/LH ratio were significantly decreased (3.5–3.0 µg/l, 0.9–0.4, 7.9–4.5, respectively) while LH and FSH (4.2–8.5 IU/l, 6.0–21.9 IU/l) were increased. QoL and sexual functioning were significantly impaired. However, there was no statistical correlation between testicular radiation dose and changes in hormone levels, QoL, or sexual functioning.

Conclusion

Multimodal treatment for rectal cancer including RCT leads to hormone level changes and to impaired QoL and sexual functioning. However, because there was no apparent correlation between the analyzed parameters, QoL is probably also influenced by other factors, e.g., psychosocial aspects.

Keywords

Rectal cancer Neoadjuvant radiochemotherapy Quality of life Sexual functioning Hormonal changes 

Strahlendosis am Hoden nach multimodaler kurativer Therapie lokal fortgeschrittener Rektumkarzinome

Einfluss auf Hormonstatus, Lebensqualität und Sexualfunktion

Zusammenfassung

Ziel

Die vorliegende Arbeit untersucht prospektiv den Einfluss der Strahlendosis am Hoden auf Hormonstatus, Lebensqualität und Sexualfunktion bei Männern nach multimodaler kurativer Therapie (neoadjuvante Radiochemotherapie, TME und adjuvante Chemotherapie) lokal fortgeschrittener Rektumkarzinome.

Patienten und Methodik

Von November 2007 bis November 2009 wurden 83 männliche Patienten an der Universitätsmedizin Göttingen mit einer neoadjuvanten Radiochemotherapie (RCT; Gesamtdosis 50,4 Gy; begleitende Chemotherapie mit 2 Zyklen 5-Fluoruracil (5-FU) oder 5-FU und Oxaliplatin) bei lokal fortgeschrittenen Rektumkarzinomen behandelt. Die Dosis am Hoden wurde analysiert und mit dem Hormonstatus [luteinisierendes Hormon (LH), follikelstimulierendes Hormon (FSH), Testosteron und dem freien Androgenindex (FAI)], der Lebensqualität (QoL) und der Sexualfunktion vor und bis zu einem Jahr nach RCT korreliert.

Ergebnisse

Mittelwert der Dosis am Hoden war 3,9 Gy (0,28–11,98 Gy). Die Hodendosis war signifikant höher bei Tumorlokalisationen < 6 cm ab ano (p < 0,05). Ein Jahr nach RCT waren das Testosteron, der Testosteron/LH-Index und der FAI/LH-Index signifikant verringert (jeweils 3,5–3,0 µg/l; 0,9–0,4; 7,9–4,5), LH und FSH (4,2–8,5 IU/l; 6,0–21,9 IU/l) waren gegenregulatorisch erhöht. Die QoL und die Sexualfunktion waren signifikant verringert. Es fand sich allerdings keine statistisch signifikante Korrelation zwischen der Hodendosis und dem Hormonstatus, der QoL oder der Sexualfunktion.

Schlussfolgerung

Nach multimodaler Therapie lokal fortgeschrittener Rektumkarzinome kommt es zu Veränderungen der Hormonspiegel sowie subjektiver Einschätzung der QoL. Es konnte jedoch im untersuchten Kollektiv keine statistisch signifikante Korrelation zwischen den untersuchten Faktoren gefunden werden. Möglicherweise ist die subjektive Einschätzung der QoL von weiteren Faktoren abhängig, die auch im – objektiv nur schwer messbaren – psychosozialen Bereich angesiedelt sein könnten.

Schlüsselwörter

Rektumkarzinom Neoadjuvante Radiochemotherapie Lebensqualität Sexualfunktion Hormonelle Veränderungen 

References

  1. 1.
    Edwards BK, Brown ML, Wingo PA et al (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407–1427PubMedCrossRefGoogle Scholar
  2. 2.
    Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRefGoogle Scholar
  3. 3.
    Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRefGoogle Scholar
  4. 4.
    Welzel G, Hagele V, Wenz F et al (2011) Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. Strahlenther Onkol 187:175–182PubMedCrossRefGoogle Scholar
  5. 5.
    Allal AS, Gervaz P, Gertsch P et al (2005) Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study. Int J Radiat Oncol Biol Phys 61:1129–1135PubMedCrossRefGoogle Scholar
  6. 6.
    Maurer CA (2005) Urinary and sexual function after total mesorectal excision. Recent Results Cancer Res 165:196–204PubMedCrossRefGoogle Scholar
  7. 7.
    Dueland S, Guren MG, Olsen DR et al (2003) Radiation therapy induced changes in male sex hormone levels in rectal cancer patients. Radiother Oncol 68:249–253PubMedCrossRefGoogle Scholar
  8. 8.
    Yoon FH, Perera F, Fisher B et al (2009) Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients. Int J Radiat Oncol Biol Phys 74:1186–1190PubMedCrossRefGoogle Scholar
  9. 9.
    Izard MA (1995) Leydig cell function and radiation: a review of the literature. Radiother Oncol 34:1–8PubMedCrossRefGoogle Scholar
  10. 10.
    Hermann RM, Henkel K, Christiansen H et al (2005) Testicular dose and hormonal changes after radiotherapy of rectal cancer. Radiother Oncol 75:83–88PubMedCrossRefGoogle Scholar
  11. 11.
    Vorwerk H, Hermann RM, Christiansen H et al (2007) A special device (double-hole belly board) and optimal radiation technique to reduce testicular radiation exposure in radiotherapy of rectal cancer. Radiother Oncol 84:320–327PubMedCrossRefGoogle Scholar
  12. 12.
    Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRefGoogle Scholar
  13. 13.
    Sprangers MA, Velde A te, Aaronson NK (1999) The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European organization for research and treatment of cancer study group on quality of life. Eur J Cancer 35:238–247PubMedCrossRefGoogle Scholar
  14. 14.
    Rosen RC, Riley A, Wagner G et al (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830PubMedCrossRefGoogle Scholar
  15. 15.
    Bruheim K, Svartberg J, Carlsen E et al (2008) Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH. Int J Radiat Oncol Biol Phys 70:722–727PubMedCrossRefGoogle Scholar
  16. 16.
    Bruheim K, Guren MG, Skovlund E et al (2010) Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76:1005–1011PubMedCrossRefGoogle Scholar
  17. 17.
    Bruheim K, Guren MG, Dahl AA et al (2010) Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76:1012–1017PubMedCrossRefGoogle Scholar
  18. 18.
    Bruheim K, Tveit KM, Skovlund E et al (2010) Sexual function in females after radiotherapy for rectal cancer. Acta Oncol 49:826–832PubMedCrossRefGoogle Scholar
  19. 19.
    Marijnen CA, Velde CJ van de, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858PubMedCrossRefGoogle Scholar
  20. 20.
    Marquis R, Lasry JC, Heppell J et al (1992) Quality of life of patients after restorative surgery for cancer of the rectum. Ann Chir 46:830–838PubMedGoogle Scholar
  21. 21.
    Inomata A, Matsumoto H, Horii I (2000) Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 18). Comparative 4 and 2 weeks oral repeated dosing studies on male reproductive organs in rats treated with 5-fluorouracil. J Toxicol Sci 25 Spec No:179–186Google Scholar
  22. 22.
    Takizawa S, Horii I (2002) Endocrinological assessment of toxic effects on the male reproductive system in rats treated with 5-fluorouracil for 2 or 4 weeks. J Toxicol Sci 27:49–56PubMedCrossRefGoogle Scholar
  23. 23.
    Kinsella TJ (1989) Effects of radiation therapy and chemotherapy on testicular function. Prog Clin Biol Res 302:157–171PubMedGoogle Scholar
  24. 24.
    Barni S, Lissoni P, Tancini G et al (1987) Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients. Tumori 73:181–185PubMedGoogle Scholar
  25. 25.
    Nishizawa Y, Ito M, Saito N et al (2011) Male sexual dysfunction after rectal cancer surgery. Int J Colorectal Dis 26:1541–1548PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  • S. Hennies
    • 1
  • H.A. Wolff
    • 1
  • K. Jung
    • 2
  • M. Rave-Fränk
    • 1
  • J. Gaedcke
    • 3
  • M. Ghadimi
    • 3
  • C.F. Hess
    • 1
  • H. Becker
    • 3
  • R.M. Hermann
    • 1
    • 4
  • H. Christiansen
    • 1
    • 5
  1. 1.Department of RadiotherapyUniversity Medicine GoettingenGöttingenGermany
  2. 2.Department of Medical StatisticsUniversity Medicine GoettingenGöttingenGermany
  3. 3.Department of General SurgeryUniversity Medicine GoettingenGöttingenGermany
  4. 4.RadiotherapyÄrztehaus an der AmmerlandklinikWesterstedeGermany
  5. 5.Department of RadiotherapyHannover Medical SchoolHannoverGermany

Personalised recommendations